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sible cause of fever or seen as a co-infection to malaria. The
ﬁndings further strengthen the importance of vector control meas-
ures.
The collected material will be further analysed. Neutralization
test might be a way forward, as looking at IgM-reactivity and for
the microbes by PCR.
*Niklasson; Epidem. Inf. (1987), 99, 517-522
http://dx.doi.org/10.1016/j.ijid.2014.03.903
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Background: Emerging and infectious diseases threaten health,
security, and the global economy. However, little is known about
investments in research to tackle outbreaks and innovate new tools
for infectious disease control.
Methods & Materials: We systematically searched databases
and websites for information on research investments for the
period 1997-2010. We identiﬁed 325,922 studies for screening,
included 6,165 studies in the initial analysis, and identiﬁed 654
studies on emerging infectious diseases in the ﬁnal analysis.
Results: We identiﬁed a total research investment in emerg-
ing infectious diseases of £199 million, accounting for 7.7% of a
total research investment in infectious diseases of £2.6 billion. In
comparison, investment in HIV research amounted to £478million
(18.4% of total investment).
Diagnostic tools for control accounted for £9.8 million (4.9%)
across 66 studies. Studies assessing therapeutics accounted for
£20.0 million (9.9%) across 35 studies. Vaccine research attracted
the least funding for tools to tackle emerging infectious diseases,
with £11.5 million (5.8%) across 24 studies.
Hepatitis C received the most investment with £59.7
million (30.0%), followed by prion research with £33.5 mil-
lion (16.8%),Campylobacter jejuniwith £24.1 million (12.1%),
andHelicobacter pyloriwith £15.1 million (7.6%). Although total
inﬂuenza investment was £80.1 million, funding speciﬁcally for
H5N1 inﬂuenza virus was £13.7 million (6.9%) and for H1N1
inﬂuenza virus was £10.8 million (5.4%).
Public funding accounted for £144.0 million (72.3%) across
361 studies with philanthropic funding awarding £40.6 million
(20.4%) across 173. Preclinical research attracted the most invest-
ment with £142.4 million (71.5%) followed by epidemiological and
operational researchwith £42.1million (21.2%) and product devel-
opment research with £12.2 million (6.1%). Phase 1, 2, 3 clinical
trials was the least well-funded type of research with £2.5 million
(1.2%).
Conclusion: Emerging infectious diseases receives small
amounts of funding compared to other scientiﬁc disciplines, with
the exception of HIV. It is essential that we map, monitor and
evaluate emerging infectious disease research funding given their
importance to global health security.
http://dx.doi.org/10.1016/j.ijid.2014.03.904
Type: Poster Presentation
Final Abstract Number: 51.037
Session: Emerging Infectious Diseases
Date: Friday, April 4, 2014
Time: 12:45-14:15
Room: Ballroom
Neurological aspects of human parvovirus B19
infection: A systematic analysis
F. Barah1,∗, S. Whiteside2, S. Batista3, J. Morris2
1 Center for Neuroscience and Cell Biology (CNC),
Coimbra, Portugal
2 University Hospital of South Manchester,
Manchester, United Kingdom
3 Coimbra Hospital and University Centre, Coimbra,
Portugal
Background: Parvovirus B19 has been linkedwith various clini-
cal syndromes including neurological manifestations. However, its
role in the latter remains not completely understood. Although, the
last 10 years witnessed a surge of case reports on B19-associated
neurological aspects, the literature data remains scattered and het-
erogeneous, and epidemiological information on the incidence of
B19-associated neurological aspects cannot be accurately extrapo-
lated. Our aim was to systematically identify the characteristics of
cases of B19-associated neurological manifestations.
Methods & Materials: A computerized systematic review of
existing literature concerning cases of B19-related neurological
aspects was conducted using all databases included in Web of
Knowledge and PubMed database following PRISMA guidelines.
Data were summarized using percentages and cross tabulations.
The 95% conﬁdence intervals for percentageswere calculated using
the Wilson method. All statistical analyses used the conventional
two-sided 5% signiﬁcance level and were carried out using SPSS
version 20 and CIA version 2.0.
Results: As shown in Figure 1, 89 articles describing 129 cases
of B19-related neurological aspects were considered eligible and
further analysed; 79 (61·2%) were associated with central nervous
system manifestations, 41 (31·8%) were associated with peripheral
nervous system manifestations and nine (7·0%) were linked with
myalgic encephalomyelitis. The majority of the cases (50/129) had
encephalitis. Clinical characteristic features of the cases were ana-
lysed, and possible pathological mechanisms were also described.
Conclusion: B19 should be included in differential diagnosis of
encephalitic syndrome of unknown aetiology in all age groups. In
addition, B19 should be included in differential diagnosis of some
peripheral nervous system manifestations such as neuralgic amy-
otrophy. Diagnosis should rely on investigation of anti-B19 IgM
antibodies and B19 DNA in serum or CSF. Treatment of severe cases
couldbeneﬁt fromacombined regimeof intravenous immunoglob-
ulins and steroids.
To conﬁrm these outcomes, goal-targeted studies are recom-
mended to exactly identify epidemiological scenarios and explore
potential pathogenic mechanisms of these complications. Per-
forming retrospective and prospective, and multicenter studies
concerning B19 and neurological aspects are in demand.
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